WO2023058051A1 - Process to produce a pharmaceutical composition - Google Patents
Process to produce a pharmaceutical composition Download PDFInfo
- Publication number
- WO2023058051A1 WO2023058051A1 PCT/IN2022/050866 IN2022050866W WO2023058051A1 WO 2023058051 A1 WO2023058051 A1 WO 2023058051A1 IN 2022050866 W IN2022050866 W IN 2022050866W WO 2023058051 A1 WO2023058051 A1 WO 2023058051A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibody
- temperature
- cell culture
- antibody composition
- culture
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 13
- 230000008569 process Effects 0.000 title claims abstract description 11
- 239000008194 pharmaceutical composition Substances 0.000 title description 3
- 238000004113 cell culture Methods 0.000 claims abstract description 33
- 239000000203 mixture Substances 0.000 claims abstract description 31
- 210000004962 mammalian cell Anatomy 0.000 claims abstract description 17
- 238000012258 culturing Methods 0.000 claims abstract description 13
- 210000004027 cell Anatomy 0.000 claims description 22
- 230000002378 acidificating effect Effects 0.000 claims description 6
- 102000006495 integrins Human genes 0.000 claims description 6
- 108010044426 integrins Proteins 0.000 claims description 6
- 229960004914 vedolizumab Drugs 0.000 claims description 4
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims 1
- 230000004481 post-translational protein modification Effects 0.000 description 7
- 239000006143 cell culture medium Substances 0.000 description 6
- 229960000106 biosimilars Drugs 0.000 description 5
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 4
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 241000699802 Cricetulus griseus Species 0.000 description 3
- 150000001413 amino acids Chemical group 0.000 description 3
- 238000004255 ion exchange chromatography Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 208000011231 Crohn disease Diseases 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 230000003698 anagen phase Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 238000005277 cation exchange chromatography Methods 0.000 description 2
- 239000012526 feed medium Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000001155 isoelectric focusing Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 241000894007 species Species 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 101100454807 Caenorhabditis elegans lgg-1 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 238000010420 art technique Methods 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 210000000270 basal cell Anatomy 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 229940126587 biotherapeutics Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000009144 enzymatic modification Effects 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- HQPMKSGTIOYHJT-UHFFFAOYSA-N ethane-1,2-diol;propane-1,2-diol Chemical compound OCCO.CC(O)CO HQPMKSGTIOYHJT-UHFFFAOYSA-N 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
Definitions
- the Biological material used in the invention was not obtained from India.
- the present invention relates to a cell culture process for culturing mammalian cells producing a pharmaceutical composition.
- the invention provides a mammalian cell culture process comprising culturing the mammalian cells at a pH range of 6.7 to 7.2 and performing a temperature shift, to obtain an antibody composition comprising charge variant.
- Monoclonal antibodies are the fastest growing pharmaceutical products used for diseases like cancer, autoimmune, cardiovascular and inflammatory disorders. They are produced in mammalian cells like Chinese hamster ovary (CHO) cells since they have post-translational modifications (PTMs) which are integral to the effector function of the therapeutic antibody molecules. PTMs refer to enzymatic modification of proteins following its translation which generally result in mature protein/antibody. It may also lead to various variants viz. glycoforms, charge variants and size variants. As a result of these modifications, the structure, stability and function of the proteins are altered. Hence, it is critical to monitor the levels of these variants for the antibody to maintain its biological activity and stability.
- PTMs post-translational modifications
- Vedolizumab a recombinant humanized lgG1 monoclonal antibody binding to human a4[37 integrin, is approved for the treatment of moderate to severely active ulcerative colitis and Crohn’s disease in adults who have failed at least one conventional therapy. It consists of an asparagine-linked glycosylation site on each of the heavy chain. (Wyant et. al. An Overview of the Mechanism of Action of the Monoclonal Antibody Vedolizumab. Journal of Crohn's and Colitis, 2016, 1437-1444). Biosimilars , sometimes called similar biological medicinal product or ‘follow-on biologic’ or ‘subsequent entry biologic’, include therapeutic mAbs which are similar to already licensed therapeutic product (the ‘reference product’).
- biosimilars must demonstrate high similarity to the reference product, in terms of quality characteristics, biological activity, safety and efficacy, in order to have marketing approval (Sullivan, P.M. and L.M. DiGrazia, Analytic characterization of biosimilars. Am J Health SystPharm, 2017. 74(8): p. 568-579; Guttman et. al. Assessing Glycosimilarity of Biotherapeutics. 2018 https://sciex.com/content/dam/SCIEX/pdf/tech- notes/all/Glycosimilarity. pdf) .
- the present invention relates to a cell culture process for producing an antibody composition, the process comprising culturing mammalian cells at a pH range of 6.7 to 7.2, performing a temperature shift from a first culture temperature to a second culture temperature, thereby obtaining an antibody composition comprising charge variants, wherein the percentage of basic charge variants is not less than 16%.
- the present invention relates to a cell culture process for producing a pharmaceutical monoclonal antibody composition, the process comprising culturing mammalian cells expressing the monoclonal antibody at a pH range of about 6.7 to about 7.2, performing a temperature shift from a first culture temperature to a second culture temperature, thereby obtaining an antibody composition comprising charge variant. Further, the present invention discloses that the obtained antibody composition comprises of basic charge variants, wherein the percentage of basic charge variants is not less than 16%.
- antibody or “monoclonal antibody” refers to an intact antibody or an antigen binding fragment thereof.
- antibody composition refers to a population of antibody molecules or fragments thereof that is produced by mammalian cell culture.
- the population of antibody molecules may have one or several post translational modifications (PTM), imparting the antibody molecules a different molecular weight, charge, solubility or combinations thereof.
- PTM post translational modifications
- biosimilar refers to a recombinant pharmaceutical protein, commonly with identical amino acid sequence to a reference product that contains, similar, very similar to or same post-translational modifications as the reference product yielding no clinically meaningful difference in terms of safety, purity and potency.
- cell culture process refers to a process of culturing a population of cells that are capable of producing recombinant protein of interest or antibody.
- charge variants i.e. variant species having acidic or basic charge due to various post translational modification can be detected by Ion exchange chromatography (IEX) or Isoelectric focusing (IEF).
- main peak refers to the peak that elutes in abundance (major peak) during ion exchange chromatography.
- ACV acidic variant peak
- BCV basic variant peak
- reference product refers to a currently or previously marketed recombinant protein, also described as the "originator product” or "branded product” serving as a comparator in the studies.
- temperature shift refers to the change in temperature during the cell culture process.
- the present invention provides a cell culture process for culturing mammalian cells expressing an antibody, the process comprising culturing the cells at a pH range of 6.7 to 7.2 and lowering of temperature of the cell culture from a first temperature to a second temperature, to obtain antibody composition comprising charge variants.
- mammalian cell or cell type which is suitable for expression of recombinant proteins in a cell culture medium may be used for the present invention.
- mammalian cells that may be used with the present invention include Chinese hamster ovary (CHO) cells, baby hamster kidney (BHK21 ) cells and murine myeloma cells (NSO and Sp2/0) human retinoblasts (PER.C6 cell line), human embryonic kidney cell line (HEK-293 cell line) (Dumont, J., et al., Human cell lines for biopharmaceutical manufacturing: history, status, and future perspectives. Crit Rev Biotech not, 2016. 36(6): p. 1110-1122).
- CHO cell lines expressing recombinant proteins may be used in accordance with the present invention.
- Cell culture medium is understood by those skilled in the art to refer to a nutrient solution in which cells, such as animal or mammalian cells, are grown.
- a cell culture medium generally includes one or more of the following components: an energy source (e.g., a carbohydrate such as glucose); amino acids; vitamins; lipids or free fatty acids; and trace elements, e.g., inorganic compounds or naturally occurring elements in the micromolar range.
- Cell culture medium can also contain additional components, such as hormones and other growth factors (e.g., insulin, transferrin, epidermal growth factor, serum, and the like); salts (e.g., calcium, magnesium and phosphate); sugars (e.g.
- Mannose, galactose, fucose amino acids (glutamine); buffers (e.g., HEPES); nucleosides and bases (e.g., adenosine, thymidine, hypoxanthine ); antibiotics (e.g., gentamycin); and cell protective agents (e.g., a Pluronic polyol (Pluronic F68).
- buffers e.g., HEPES
- nucleosides and bases e.g., adenosine, thymidine, hypoxanthine
- antibiotics e.g., gentamycin
- cell protective agents e.g., a Pluronic polyol (Pluronic F68).
- DMEM Dulbecco's Modified Eagles Medium
- RPMI-1640 Medium Sigma-Aldrich
- EX-CELL® Advanced CHO Fed-batch Medium Sigma-Aldrich
- Cell BoostTM 7a and 7b GE Healthcare Bio-Sciences AB.
- DMEM Dulbecco's Modified Eagles Medium
- RPMI-1640 Medium Sigma-Aldrich
- EX-CELL® Advanced CHO Fed-batch Medium Sigma-Aldrich
- Cell BoostTM 7a and 7b GE Healthcare Bio-Sciences AB
- the methods described in the present invention are in recognition of the fact that various parameters of the cell culture process may be used to obtain antibody composition comprising various variants.
- the cell culture process envisages culturing the cells at a pH range of about 6.7 to about 7.2 and performing a temperature shift.
- the present invention discloses a cell culture process for producing an antibody composition, wherein the said process comprises a) providing mammalian cells expressing the said antibody b) culturing the cells at a pH range of about 6.7 to about 7.2 c) performing a temperature shift during the cell culture from a first culture temperature to a second culture temperature, wherein the second culture temperature is lower than the first culture temperature d) recovering the said recombinant antibody composition wherein the antibody composition produced comprises of not less than 16.45% basic charge variants.
- the present invention discloses a cell culture process for producing an antibody composition, wherein the said process comprises a) providing mammalian cells expressing the said antibody b) culturing the cells at a pH range of about 6.7 to about 7.2 c) performing a temperature shift during the cell culture from a first culture temperature to a second culture temperature, wherein the second culture temperature is lower than the first culture temperature d) recovering the said recombinant antibody composition wherein the antibody composition produced comprises of about 19.1 % acidic variants, about 16.45% or more basic charge variants.
- the present invention discloses a cell culture process for producing an antibody composition, wherein the said process comprises a) providing mammalian cells expressing the said antibody b) culturing the cells at a pH range of about 6.7 to about 7.2 c) performing a temperature shift during the cell culture from a first culture temperature to a second culture temperature, wherein the second culture temperature is lower than the first culture temperature d) recovering the said recombinant antibody composition wherein the antibody composition produced comprises of about 19.1 % acidic variant, about 64.5% main species of the antibody and about 16.45% of basic variant.
- the temperature shift is performed on day 5 of the cell culture, day 6 of the cell culture, or day 7 of the cell culture. In yet another embodiment, the temperature shift is performed on day 6 of the cell culture.
- the difference between the first culture temperature and the second culture temperature is about 6.5.
- the culture temperature before the temperature shift is about 37°C and the culture temperature after the temperature shift is about 30°C.
- the antibody produced in any of the above embodiment is a biosimilar antibody.
- the antibody produced using the present invention is an anti a4[37 integrin antibody.
- the antibody produced using the present invention is vedolizumab.
- Table 1 The composition and titer of the anti-a4[37 integrin antibody.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The present invention relates to a cell culture process for producing a pharmaceutical monoclonal antibody composition, the process comprising culturing mammalian cells expressing the monoclonal antibody at a pH range of about 6.7 to about 7.2, performing a temperature shift from a first culture temperature to a second culture temperature, thereby obtaining an antibody composition comprising charge variants. Further, the present invention discloses that the obtained antibody composition comprises of basic charge variants, wherein the percentage of basic charge variants is not less than 16%.
Description
PROCESS TO PRODUCE A PHARMACEUTICAL COMPOSITION
FIELD OF INVENTION
The Biological material used in the invention was not obtained from India.
The present invention relates to a cell culture process for culturing mammalian cells producing a pharmaceutical composition. The invention provides a mammalian cell culture process comprising culturing the mammalian cells at a pH range of 6.7 to 7.2 and performing a temperature shift, to obtain an antibody composition comprising charge variant.
BACKGROUND OF THE INVENTION
Monoclonal antibodies (mAbs) are the fastest growing pharmaceutical products used for diseases like cancer, autoimmune, cardiovascular and inflammatory disorders. They are produced in mammalian cells like Chinese hamster ovary (CHO) cells since they have post-translational modifications (PTMs) which are integral to the effector function of the therapeutic antibody molecules. PTMs refer to enzymatic modification of proteins following its translation which generally result in mature protein/antibody. It may also lead to various variants viz. glycoforms, charge variants and size variants. As a result of these modifications, the structure, stability and function of the proteins are altered. Hence, it is critical to monitor the levels of these variants for the antibody to maintain its biological activity and stability.
Vedolizumab, a recombinant humanized lgG1 monoclonal antibody binding to human a4[37 integrin, is approved for the treatment of moderate to severely active ulcerative colitis and Crohn’s disease in adults who have failed at least one conventional therapy. It consists of an asparagine-linked glycosylation site on each of the heavy chain. (Wyant et. al. An Overview of the Mechanism of Action of the Monoclonal Antibody Vedolizumab. Journal of Crohn's and Colitis, 2016, 1437-1444).
Biosimilars , sometimes called similar biological medicinal product or ‘follow-on biologic’ or ‘subsequent entry biologic’, include therapeutic mAbs which are similar to already licensed therapeutic product (the ‘reference product’). Regulatory agencies mandate that biosimilars must demonstrate high similarity to the reference product, in terms of quality characteristics, biological activity, safety and efficacy, in order to have marketing approval (Sullivan, P.M. and L.M. DiGrazia, Analytic characterization of biosimilars. Am J Health SystPharm, 2017. 74(8): p. 568-579; Guttman et. al. Assessing Glycosimilarity of Biotherapeutics. 2018 https://sciex.com/content/dam/SCIEX/pdf/tech- notes/all/Glycosimilarity. pdf) .
Therefore, the present invention relates to a cell culture process for producing an antibody composition, the process comprising culturing mammalian cells at a pH range of 6.7 to 7.2, performing a temperature shift from a first culture temperature to a second culture temperature, thereby obtaining an antibody composition comprising charge variants, wherein the percentage of basic charge variants is not less than 16%.
SUMMARY OF THE INVENTION
The present invention relates to a cell culture process for producing a pharmaceutical monoclonal antibody composition, the process comprising culturing mammalian cells expressing the monoclonal antibody at a pH range of about 6.7 to about 7.2, performing a temperature shift from a first culture temperature to a second culture temperature, thereby obtaining an antibody composition comprising charge variant. Further, the present invention discloses that the obtained antibody composition comprises of basic charge variants, wherein the percentage of basic charge variants is not less than 16%.
DETAILED DESCRIPTION OF THE INVENTION
Definitions
The term about refers to a range of values that are similar to the stated reference value to a range of values that fall within 25, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11 , 10, 9, 8, 7, 6, 5, 4, 3, 2, 1 percent or less of the stated reference value.
The term “antibody” or “monoclonal antibody” refers to an intact antibody or an antigen binding fragment thereof.
The term “antibody composition” refers to a population of antibody molecules or fragments thereof that is produced by mammalian cell culture. The population of antibody molecules may have one or several post translational modifications (PTM), imparting the antibody molecules a different molecular weight, charge, solubility or combinations thereof.
The term "biosimilar" refers to a recombinant pharmaceutical protein, commonly with identical amino acid sequence to a reference product that contains, similar, very similar to or same post-translational modifications as the reference product yielding no clinically meaningful difference in terms of safety, purity and potency.
The term “cell culture process” as used herein refers to a process of culturing a population of cells that are capable of producing recombinant protein of interest or antibody.
The term “charge variants” i.e. variant species having acidic or basic charge due to various post translational modification can be detected by Ion exchange chromatography (IEX) or Isoelectric focusing (IEF). The term ‘main peak’ refers to the peak that elutes in abundance (major peak) during ion exchange chromatography. In particular, during cation exchange chromatography (CEX), the peak that elutes earlier than the main peak has charge that is acidic relative to main peak and is termed as acidic variant peak (ACV). The peak that elutes later than the main peak has charge that is basic relative to the main peak and is termed as basic variant peak (BCV).
The term reference product refers to a currently or previously marketed recombinant protein, also described as the "originator product" or "branded product" serving as a comparator in the studies.
The term “temperature shift” refers to the change in temperature during the cell culture process.
DETAILED DESCRIPTION OF THE EMBODIMENTS
The present invention provides a cell culture process for culturing mammalian cells expressing an antibody, the process comprising culturing the cells at a pH range of 6.7 to 7.2 and lowering of temperature of the cell culture from a first temperature to a second temperature, to obtain antibody composition comprising charge variants.
Any mammalian cell or cell type which is suitable for expression of recombinant proteins in a cell culture medium may be used for the present invention. Non-limiting examples of mammalian cells that may be used with the present invention include Chinese hamster ovary (CHO) cells, baby hamster kidney (BHK21 ) cells and murine myeloma cells (NSO and Sp2/0) human retinoblasts (PER.C6 cell line), human embryonic kidney cell line (HEK-293 cell line) (Dumont, J., et al., Human cell lines for biopharmaceutical manufacturing: history, status, and future perspectives. Crit Rev Biotech not, 2016. 36(6): p. 1110-1122). In a preferred embodiment, CHO cell lines expressing recombinant proteins may be used in accordance with the present invention.
Cell culture medium is understood by those skilled in the art to refer to a nutrient solution in which cells, such as animal or mammalian cells, are grown. A cell culture medium generally includes one or more of the following components: an energy source (e.g., a carbohydrate such as glucose); amino acids; vitamins; lipids or free fatty acids; and trace elements, e.g., inorganic compounds or naturally occurring elements in the micromolar range. Cell culture medium can also contain additional components, such
as hormones and other growth factors (e.g., insulin, transferrin, epidermal growth factor, serum, and the like); salts (e.g., calcium, magnesium and phosphate); sugars (e.g. mannose, galactose, fucose); amino acids (glutamine); buffers (e.g., HEPES); nucleosides and bases (e.g., adenosine, thymidine, hypoxanthine ); antibiotics ( e.g., gentamycin); and cell protective agents ( e.g., a Pluronic polyol (Pluronic F68). Commercially available media can be utilized in accordance with the present invention, for example, Dulbecco's Modified Eagles Medium (DMEM, Sigma-Aldrich); RPMI-1640 Medium (Sigma-Aldrich); EX-CELL® Advanced CHO Fed-batch Medium (Sigma-Aldrich); Cell Boost™ 7a and 7b (GE Healthcare Bio-Sciences AB). One skilled in the art would appreciate that some cell culture media are suited to support cells through their initial growth phase (basal medium) while some sustain cells through the later growth phase and production phase of cell culture (feed medium), and would be able to choose appropriate culture medium.
The methods described in the present invention are in recognition of the fact that various parameters of the cell culture process may be used to obtain antibody composition comprising various variants. In an embodiment, the cell culture process envisages culturing the cells at a pH range of about 6.7 to about 7.2 and performing a temperature shift.
A person of ordinary skill in the art would be able to characterize and analyse the various antibody variants present in the antibody composition produced by the cell culture process described herein using the state of the art techniques.
In an embodiment, the present invention discloses a cell culture process for producing an antibody composition, wherein the said process comprises a) providing mammalian cells expressing the said antibody b) culturing the cells at a pH range of about 6.7 to about 7.2
c) performing a temperature shift during the cell culture from a first culture temperature to a second culture temperature, wherein the second culture temperature is lower than the first culture temperature d) recovering the said recombinant antibody composition wherein the antibody composition produced comprises of not less than 16.45% basic charge variants.
In an embodiment, the present invention discloses a cell culture process for producing an antibody composition, wherein the said process comprises a) providing mammalian cells expressing the said antibody b) culturing the cells at a pH range of about 6.7 to about 7.2 c) performing a temperature shift during the cell culture from a first culture temperature to a second culture temperature, wherein the second culture temperature is lower than the first culture temperature d) recovering the said recombinant antibody composition wherein the antibody composition produced comprises of about 19.1 % acidic variants, about 16.45% or more basic charge variants.
In an embodiment, the present invention discloses a cell culture process for producing an antibody composition, wherein the said process comprises a) providing mammalian cells expressing the said antibody b) culturing the cells at a pH range of about 6.7 to about 7.2 c) performing a temperature shift during the cell culture from a first culture temperature to a second culture temperature, wherein the second culture temperature is lower than the first culture temperature d) recovering the said recombinant antibody composition
wherein the antibody composition produced comprises of about 19.1 % acidic variant, about 64.5% main species of the antibody and about 16.45% of basic variant.
In any of the embodiments mentioned above, the temperature shift is performed on day 5 of the cell culture, day 6 of the cell culture, or day 7 of the cell culture. In yet another embodiment, the temperature shift is performed on day 6 of the cell culture.
In any of the embodiments mentioned above, the difference between the first culture temperature and the second culture temperature is about 6.5. In another embodiment, the culture temperature before the temperature shift is about 37°C and the culture temperature after the temperature shift is about 30°C.
In a further embodiment, the antibody produced in any of the above embodiment is a biosimilar antibody.
In yet another embodiment, the antibody produced using the present invention is an anti a4[37 integrin antibody. In a preferred embodiment, the antibody produced using the present invention is vedolizumab.
Those skilled in the art will recognize that several embodiments are possible within the scope and spirit of this invention. The invention will now be described in greater detail by reference to the following non-limiting example. The following example further illustrates the invention but, of course, should not be construed as in any way limiting its scope.
EXAMPLE
An anti-a4[37 integrin antibody having a heavy chain and light chain as described in W02007061679A1 was cloned and expressed in a recombinant CHO (rCHO) cell line using techniques described in detail in “Molecular Cloning: A Laboratory Manual (Fourth Edition)”. rCHO cells expressing the antibody were seeded at a density of about 0.5 million
cells/mL in basal cell culture medium and cultured at an initial temperature of 36.5°C. The pH range of the cell culture is maintained between pH 6.7 to 7.2. On day 6, a temperature shift was performed, thereby reducing the culture temperature to 30°C. The cell culture was added with 25% feed medium. The culture was harvested on day 13. The antibody composition and titer obtained is depicted in Table 1 .
Table 1. The composition and titer of the anti-a4[37 integrin antibody.
Claims
1 . A cell culture process for producing a recombinant antibody composition comprising charge variants of the antibody, wherein the said process comprises a) providing mammalian cells expressing the said antibody b) culturing the cells at a pH range of about 6.7 to about 7.2 c) performing a temperature shift during the cell culture from a first culture temperature to a second culture temperature, wherein the second culture temperature is about 6.5°C lower than the first culture temperature d) recovering the said recombinant antibody composition wherein the antibody composition produced comprises of at least 16.45% basic charge variants of the antibody.
2. A cell culture process as claimed in claim 1 , wherein the antibody composition produced further comprises of about 19.1 % acidic variants and/or about 64.5% main species of the antibody.
3. A cell culture process as claimed in claim 1 , wherein the first culture temperature before the temperature shift is about 36.5°C and the second culture temperature after the temperature shift is about 30°C.
4. A cell culture process as claimed in any of the preceding claims, wherein the antibody composition produced is an anti a4[37 integrin antibody composition.
5. A cell culture process as claimed in claim 4, wherein the anti a4[37 integrin antibody is vedolizumab.
9
6. A cell culture process as claimed in any of the preceding claims, wherein the mammalian cell used to express the antibody composition is CHO cells.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN202141044972 | 2021-10-04 | ||
| IN202141044972 | 2021-10-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2023058051A1 true WO2023058051A1 (en) | 2023-04-13 |
Family
ID=85803258
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/IN2022/050866 WO2023058051A1 (en) | 2021-10-04 | 2022-09-28 | Process to produce a pharmaceutical composition |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2023058051A1 (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017189679A1 (en) * | 2016-04-26 | 2017-11-02 | La Jolla Biologics, Inc. | Cell culture medium |
-
2022
- 2022-09-28 WO PCT/IN2022/050866 patent/WO2023058051A1/en unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017189679A1 (en) * | 2016-04-26 | 2017-11-02 | La Jolla Biologics, Inc. | Cell culture medium |
Non-Patent Citations (3)
| Title |
|---|
| KISHISHITA SHOHEI; NISHIKAWA TOMOKO; SHINODA YASUHARU; NAGASHIMA HIROAKI; OKAMOTO HIROSHI; TAKUMA SHINYA; AOYAGI HIDEKI: "Effect of temperature shift on levels of acidic charge variants in IgG monoclonal antibodies in Chinese hamster ovary cell culture", JOURNAL OF BIOSCIENCE AND BIOENGINEERING, ELSEVIER, AMSTERDAM, NL, vol. 119, no. 6, 29 November 2014 (2014-11-29), NL , pages 700 - 705, XP029586265, ISSN: 1389-1723, DOI: 10.1016/j.jbiosc.2014.10.028 * |
| MCHUGH KYLE P., XU JIANLIN, ARON KATHRYN L., BORYS MICHAEL C., LI ZHENG JIAN: "Effective temperature shift strategy development and scale confirmation for simultaneous optimization of protein productivity and quality in Chinese hamster ovary cells", BIOTECHNOLOGY PROGRESS, AMERICAN CHEMICAL SOCIETY, HOBOKEN, USA, vol. 36, no. 3, 1 May 2020 (2020-05-01), Hoboken, USA, XP055886417, ISSN: 8756-7938, DOI: 10.1002/btpr.2959 * |
| ZHANG XINTAO; SUN YA-TING; TANG HONGPING; FAN LI; HU DONGDONG; LIU JINTAO; LIU XUPING; TAN WEN-SONG: "Culture temperature modulates monoclonal antibody charge variation distribution in Chinese hamster ovary cell cultures", BIOTECHNOLOGY LETTERS, KLUWER ACADEMIC PUBLISHERS, DORDRECHT, vol. 37, no. 11, 7 July 2015 (2015-07-07), Dordrecht , pages 2151 - 2157, XP035538822, ISSN: 0141-5492, DOI: 10.1007/s10529-015-1904-3 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10711057B2 (en) | Methods of shifting an isoelectric profile of a protein product and uses thereof | |
| ES2949507T3 (en) | Procedures to increase the mannose content of recombinant proteins | |
| CN108350075B (en) | Method for increasing galactose content of recombinant protein | |
| WO2013114245A1 (en) | Process of modulating man5 and/or afucosylation content of glycoprotein composition | |
| ES2893536T3 (en) | Method for preparing antibody by regulating the sugar content of the antibody | |
| BR112015007319B1 (en) | PRODUCTION METHOD OF AN IGG1 ANTIBODY | |
| ES2908067T3 (en) | Methods to modulate protein galactosylation profiles of recombinant proteins using peracetyl galactose | |
| WO2023058051A1 (en) | Process to produce a pharmaceutical composition | |
| JP6778185B2 (en) | How to culture cells | |
| EP3099324B1 (en) | Perfusion media | |
| WO2023021532A1 (en) | A process to produce a pharmaceutical composition | |
| US10526631B1 (en) | Method of reducing serine for asparagine misincorporation | |
| US20230348850A1 (en) | Cell culture processes | |
| US12018070B2 (en) | Methods of shifting an isoelectric profile of a protein product and uses thereof | |
| US20240084355A1 (en) | Cell culture methods | |
| WO2022192055A1 (en) | Reducing high mannose glycan protein expression using guanosine 5'-monophosphate | |
| IL302740A (en) | Fab high mannose glycoforms | |
| EP4323537A1 (en) | Cell culture processes | |
| CN116903738A (en) | Low mannose type anti-human tumor necrosis factor-alpha monoclonal antibody and application thereof | |
| JPWO2020252082A5 (en) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22878108 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |